+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether casdatifan combined with cabozantinib can improve progression-free survival compared to placebo plus cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma. The study focuses on patients who have previously received anti-PD-1 or anti-PD-L1 therapies in their most recent treatment, with no more than one prior metastatic treatment regimen. This is a randomized, double-blind, active-controlled phase 3 trial aimed at advancing treatment options for this patient group. Participants will be randomly assigned to receive either casdatifan and cabozantinib or placebo and cabozantinib, both taken orally. The study includes two treatment arms one experimental arm with casdatifan and cabozantinib, and a comparator arm with placebo and cabozantinib. Treatment is ongoing, with monitoring for up to approximately 33 months for key outcomes, and follow-up for overall survival up to about 64 months. Throughout the study, participants will undergo regular assessments including imaging scans evaluated by a blinded independent review to measure tumor response and progression. Researchers will track progression-free survival, overall survival, response rates, duration of response, disease control, and treatment-related adverse events. Symptom changes will also be monitored using patient-reported measures. The total participation duration may extend up to several years to capture long-term outcomes and safety data.

Age: 18Years +All GendersPhase 3
191 locations